Pfizer’s world headquarters in New York City, US. Credit: Norbert Nagel, Mörfelden-Walldorf, Germany.

Biotechnology company Allogene Therapeutics has signed an asset contribution deal with Pfizer over allogeneic chimeric antigen receptor T cell (CAR T) therapy assets being developed to treat cancer.

Under the partnership, Pfizer will own a 25% stake in Allogene and will offer financial support to develop the CAR T portfolio, which includes 16 preclinical assets and UCART19.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Allogene intends to assume the global strategic collaboration agreement originally formed with Cellectis in 2014 for the development of ‘off-the-shelf’ CAR T immunotherapies from Pfizer.

Pfizer will continue to hold 8% shares in Cellectis.

“The portfolio of CAR T assets contributed by Pfizer will be well-positioned to rapidly advance into potential innovative new therapies, and ultimately to reach patients in need more quickly.”

Pfizer oncology research & development senior vice-president and group head Robert Abraham said: “We believe that under the strong scientific, clinical development and regulatory expertise of Allogene’s leadership team, the portfolio of CAR T assets contributed by Pfizer will be well-positioned to rapidly advance into potential innovative new therapies, and ultimately to reach patients in need more quickly.”

The deal will provide Allogene with exclusive rights for the development and commercialisation of pre-defined allogeneic UCART programmes intended for specific targets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cellectis will receive up to $2.8bn based on clinical and commercial milestones, or $185m for each of the 15 targets and tiered royalties on net sales of any associated products commercialised by Allogene.

Allogene president and CEO David Chang said: “Our mission at Allogene is to catalyse the next revolution in cancer treatment through the development of allogeneic CAR T therapies directed at blood cancers as well as solid tumours.

“We believe this collaboration fuels our mission and we look forward to partnering with Cellectis to accelerate the development of allogeneic cell therapies.”

Subject to closing conditions, the asset contribution agreement is scheduled to be completed in the second quarter of this year.